Sorry, you need to enable JavaScript to visit this website.
Skip to main content


Pearl Pugh



Pearl Pugh is Vice President and Rheumatology & Dermatology Disease Area Commercial Leader for the Immunology Therapeutic Area at Janssen Global Services. In this role, she is responsible for developing and executing the commercial strategy to support the discovery, development, and launch of new therapeutics for disease areas within Rheumatology and Dermatology. This involves leading a team of global commercial strategy and analytics professionals to develop deep insights to inform differentiated development plans and lifecycle management approaches.

Pearl also provides leadership to global commercial teams to establish effective partnerships with cross-functional and regional stakeholders to ensure worldwide launch readiness for new products and line extensions, and to maximize current in-market assets worldwide.

Prior to this role, Pearl served as the Director of Marketing, Prostate, at Janssen Oncology U.S., responsible for leading and building the prostate cancer franchise in the United States. Of note, Pearl played an instrumental part in leading a turnaround in the performance of ZYTIGA® by repositioning the product and prioritizing resource investments. This strategy led to a reversal in market share erosion and not only helped to maintain, but also grow share leadership in the highly competitive, metastatic Castration Resistant Prostate Cancer market.

Prior to joining Janssen in March of 2015, Pearl spent more than 20 years at GlaxoSmithKline (GSK) in roles of increasing responsibility across different functions and therapeutic areas, including Sales, Market Research, Payer, Marketing, and Business Development. She began her career in an international leadership development program and has lived and worked in the U.S., Europe, and Asia. Before her first role at Janssen, Pearl worked in Worldwide Business Development at GSK in the Research and Development organization, where she was Head of Business Development for Rare Diseases.

Pearl graduated from Cornell University with a Bachelor of Science degree in Applied Economics and Business Management.